What Transposon Therapeutics does

Transposon Therapeutics is a privately held, clinical-stage biotechnology company developing first-in-class therapeutics that target LINE-1 retrotransposon biology for neurodegenerative and aging-related diseases. The company's core asset, TPN-101 (Censavudine), is an orally administered, once-daily LINE-1 reverse transcriptase inhibitor designed to suppress dysregulated retrotransposon activity that drives innate immune activation and neuroinflammation. TPN-101 has been evaluated in over 250 subjects for approximately 48 weeks with favorable tolerability, completed Phase 2 studies in Progressive Supranuclear Palsy (PSP) and C9orf72-related ALS/FTD, and is advancing toward Phase 3 with FDA Fast Track Designation in PSP and inclusion in the HEALEY ALS Platform Trial. The pipeline also includes next-generation nucleoside reverse transcriptase inhibitors (Novel NRTIs) acquired in November 2024 for autoimmune, age-related, and oncology indications, plus small-molecule Protein Kinase R (PKR) inhibitors targeting downstream LINE-1 pathway mediators in CNS disease.

The company is headquartered in San Diego, California, operates with 11–50 employees, and is led by a management team collectively credited with over 30 NDA approvals and prior exits at Tobira/Allergan, Avanir/Otsuka, and Corthera/Novartis. Its go-to-market motion is enterprise and regulatory in nature: advancing candidates through clinical trials and FDA pathways, with future revenue dependent on pharmaceutical product sales or licensing transactions following approval. There is no commercial pricing or revenue today; funding to date is anchored by non-dilutive grants including up to $22 million from ARPA-H under the PROSPR program for healthy aging research and an investment from the Alzheimer's Drug Discovery Foundation to support a planned Phase 2 Alzheimer's trial. Venture backing from Canaan Partners, Osage University Partners, and Lumira Ventures anchors the cap table.

Customer and end-market exposure targets patients with high-unmet-need neurodegenerative diseases (PSP, ALS, FTD, Alzheimer's Disease) plus an emerging healthy-aging / healthspan extension opportunity. The business model is standard for an orphan and specialty neurology biotech: develop through late-stage clinical trials, secure regulatory designations to compress timelines, and ultimately monetize via direct commercialization, partnership, or acquisition.

Name

Transposon Therapeutics

Legal name

Transposon Therapeutics, Inc.

Website

https://transposonrx.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Transposon Therapeutics is a clinical-stage biotech developing TPN-101 (Censavudine), a first-in-class LINE-1 reverse transcriptase inhibitor for neurodegenerative and aging-related diseases including PSP, ALS/FTD, and Alzheimer's.

Ownership category

akta.pro rank

Product category

Neurodegenerative disease therapeutics

NAICS

Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

siRNA Therapeutics (gene silencing) (HLAAADAB)

Keywords

• Neurodegenerative disease therapeutics
• LINE-1 reverse transcriptase inhibitors
• Clinical stage biotechnology
• Age-related disease treatments
• Nucleoside reverse transcriptase inhibitors

Headquarters

HQ city

Westport

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Drug Development and Commercialization: Pre-revenue biotech company developing TPN-101 and other pipeline candidates for neurodegenerative diseases. Revenue will be generated through pharmaceutical product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Transposon Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapeutics that inhibit LINE-1 reverse transcriptase and related retrotransposon-pathway targets. Its lead asset, TPN-101 (Censavudine), is an oral once-daily first-in-class LINE-1 reverse transcriptase inhibitor being advanced for Progressive Supranuclear Palsy (PSP), C9orf72-related ALS/FTD, and Alzheimer's Disease. The pipeline additionally includes next-generation nucleoside reverse transcriptase inhibitors (NRTIs) for autoimmune, age-related, rare neurodegenerative, and oncology indications, and Protein Kinase R (PKR) inhibitors for cognitive impairment in CNS diseases.

Product overview

Transposon Therapeutics is developing a pipeline of innovative therapeutics targeting LINE-1 retrotransposons and related pathways. The core product TPN-101 (Censavudine) is a first-in-class LINE-1 reverse transcriptase inhibitor in late-stage development for multiple neurodegenerative indications. The pipeline also includes Novel NRTIs (next generation nucleoside reverse transcriptase inhibitors) in preclinical development for autoimmune, age-related, rare neurodegenerative diseases, and cancer, as well as Protein Kinase R inhibitors targeting pathways activated by LINE-1 for cognitive impairment.

Differentiator

Problem solved

Functional benefit

Products and services

• TPN-101 (Censavudine) First-in-class oral once-daily LINE-1 reverse transcriptase inhibitor in clinical development for Progressive Supranuclear Palsy (PSP), C9orf72-related Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), and Alzheimer's Disease. Has demonstrated systemic and brain bioavailability with a clinical safety database of over 250 subjects dosed for approximately 48 weeks, reductions in CSF NfL and IL-6 biomarkers in PSP, and slowed vital capacity decline in ALS.
• Novel NRTIs (next-generation nucleoside reverse transcriptase inhibitors) Next-generation nucleoside reverse transcriptase inhibitors in preclinical development for autoimmune, age-related, and rare neurodegenerative diseases, as well as cancer. Built on the company's retrotransposon/innate immunity drug discovery platform.
• Protein Kinase R (PKR) Inhibitors Small-molecule PKR inhibitors targeting downstream mediators of the LINE-1 pathway to address compromised cognition and memory associated with central nervous system diseases, including Alzheimer's Disease. Developed as potentially additive or synergistic with LINE-1 reverse transcriptase inhibition.

Quantifiable outcome

• Reductions in CSF NfL and IL-6 biomarkers in PSP patients indicating therapeutic effects on neuroinflammation and neurodegeneration
• +4 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core and minor.

• HEALEY ALS Platform TrialcoreStrategic or Co-development Partner · 4 March 2026TPN-101 was selected for inclusion in the Phase 2/3 HEALEY ALS Platform Trial, building on the success of Phase 2 study in C9orf72-related ALS. This platform trial enables efficient evaluation of multiple therapies.
• University CollaborationsminorStrategic or Co-development PartnerThe ARPA-H PROSPR program involves collaborations with several universities for studying TPN-101's effects on healthy aging and age-related diseases.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Biohaven Pharmaceuticals: Neuroscience-focused biotech developing therapies for migraine, OCD, spinal muscular atrophy, and rare neurological diseases. Comparable in disease-modification CNS pipeline and clinical-stage positioning.
• Prothena Corporation: Clinical-stage biotech developing targeted protein therapies for neurodegenerative diseases including Parkinson's, Alzheimer's, and ATTR amyloidosis. Direct peer in CNS biotech with similar stage and disease focus; Transposon's Head of Clinical Operations previously served as VP of Clinical Operations at Prothena.
• Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegenerative and lysosomal storage diseases using novel biology-driven approaches. Comparable in stage, mission (CNS disease modification), and platform-style approach to novel mechanisms.
• Amylyx Pharmaceuticals: Commercial-stage biotech with approved therapy (Relyvrio, now discontinued) for ALS and ongoing development in neurodegenerative diseases. Direct competitor in ALS clinical space and similar disease-modification thesis targeting neuroinflammation and neurodegeneration.
• Ionis Pharmaceuticals: Leader in RNA-targeted antisense therapeutics with approved drugs for neurological diseases including ALS (Qalsody for SOD1-ALS) and spinal muscular atrophy. Closest mechanistic peer given both companies develop nucleic acid-based therapeutics for CNS indications including ALS.
• Wave Life Sciences: Clinical-stage biotech developing PRISM-platform nucleic acid therapeutics including oligonucleotide therapies for ALS, Huntington's, and Duchenne muscular dystrophy. Direct peer in nucleic acid therapeutic modality applied to neurodegenerative diseases.
• Annexon Biosciences: Clinical-stage biotech developing complement-mediated therapies for neurodegenerative, autoimmune, and ophthalmic diseases. Comparable in stage, modality (biologics), and disease focus on neuroinflammation-driven CNS conditions.
• Sage Therapeutics: CNS-focused biotech with FDA-approved Zurzuvae for postpartum depression and pipeline in epilepsy and Parkinson's disease. Comparable clinical-stage neuroscience biotech pursuing differentiated CNS mechanisms.

Broad incumbents

• Alnylam Pharmaceuticals: Established leader in RNA interference (siRNA) therapeutics with multiple approved drugs and broad pipeline. Comparable in nucleic-acid therapeutic modality and CNS pipeline (e.g., Onpattro for hATTR amyloidosis) but is a larger, commercial-stage incumbent.
• Biogen: Large commercial-stage biopharmaceutical company with dominant franchise in Alzheimer's (Leqembi), ALS, and multiple sclerosis. Sets the competitive benchmark for neurodegenerative drug development and commercialization that Transposon would ultimately need to compete against or partner with.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/transposontherapeutics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Transposon Therapeutics